PXMTF.US PHAXIAM Therapeutics S.A.
- Market cap
- USD 1.01K
- P/E
- -
- P/B
- -
- ROE
- -1.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2022.
Is PXMTF.US undervalued?
Graham numberThe Graham number of PHAXIAM Therapeutics S.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PHAXIAM Therapeutics S.A. fundamental analysis
No fundamental analysis for PHAXIAM Therapeutics S.A. yet.
PHAXIAM Therapeutics S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PHAXIAM Therapeutics S.A.
PHAXIAM Therapeutics S.A., a clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France. The company develops and commercializes red cell-based therapies for cancers and orphan diseases. It develops anti-infectious therapies based on the use of bacteriophages (phages) to treat infections caused by Escherichia coli (E.coli), Pseudomonas aeruginosa (P.aeruginosa), and Staphylococcus aureus (S.aureus)…
Full company profilePHAXIAM Therapeutics S.A. financial statements
PHAXIAM Therapeutics S.A. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 |
|---|---|---|
| Income Statement | ||
| Revenue | 0.00 | 0.00 |
| Operating Income | -56.5M | -27.1M |
| EBITDA | -46.3M | 3.52M |
| Net Income | -53.8M | -228K |
| EPS | -16 | -0.07 |
| Balance Sheet | ||
| Total Assets | 66.8M | 45.8M |
| Total Liabilities | 43.9M | 22.3M |
| Shareholders' Equity | 22.8M | 23.5M |
| Cash & Short-term Investments | 33.7M | 38.8M |
| Cash Flow | ||
| Operating Cash Flow | -56.8M | -31.8M |
| Capital Expenditure | 298K | 85.0K |
| Free Cash Flow | -57.1M | -31.8M |
| Ratios | ||
| ROE | -235.5% | -1.0% |
| ROA | -80.6% | -0.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
PHAXIAM Therapeutics S.A. dividends
PHAXIAM Therapeutics S.A. has not paid dividends in the last 3 fiscal years.
Last stock split: 1:10 on Sep 18, 2023.
Who owns PHAXIAM Therapeutics S.A.
- Insiders 29.34%
- Institutions 16.93%
- Public & others 53.73%
- Shares outstanding 10.1M
- Free float 6.07M
PHAXIAM Therapeutics S.A. company profile
- Company name
- PHAXIAM Therapeutics S.A.
- Ticker
- PXMTF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 68
- Fiscal year end
- December
- Address
- 60, avenue Rockefeller, Lyon, France, 69008
- Phone
- 33 4 78 74 44 38
- Website
- phaxiam.com
About PHAXIAM Therapeutics S.A.
PHAXIAM Therapeutics S.A., a clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France. The company develops and commercializes red cell-based therapies for cancers and orphan diseases. It develops anti-infectious therapies based on the use of bacteriophages (phages) to treat infections caused by Escherichia coli (E.coli), Pseudomonas aeruginosa (P.aeruginosa), and Staphylococcus aureus (S.aureus). The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. The company was incorporated in 2004 and is headquartered in Lyon, France.
PHAXIAM Therapeutics S.A. management
10- Mr. Thibaut du FayetChief Executive Officer · born 1968
- Dr. Jérôme Bailly Pharm.D.Deputy CEO, Deputy GM, Chief Quality Officer & Qualified Person · born 1979
- Mr. Frédéric MathatChief Financial Officer
- Ms. Cindy FevreChief Scientific Officer
- Naomi EichenbaumDirector Investor Relations
- Dr. Pascal Birman M.D.Chief Medical Officer
- Dr. Philip L. Lorenzi M.D., Ph.D.Consultant & Member of Scientific Board
- Prof. Eric Raymond M.D., Ph.D.Consultant & Member of Scientific Board
- Dr. Bridget Bax Ph.D.Consultant & Member of Scientific Board
- Prof. Arthur E. Frankel M.D., Ph.D.Consultant & Member of Scientific Board